Bevacizumab for Metastatic Colorectal Cancer: A Global Cost‐Effectiveness Analysis

Effectiveness Analysis ◽

Global Cost

Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis.

10.1200/jco.2016.34.15_suppl.6518 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 6518-6518

Author(s):

Daniel A. Goldstein ◽

Qiushi Chen ◽

Turgay Ayer ◽

Kelvin K. Chan ◽

Kiran Virik ◽

...

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Effectiveness Analysis ◽

Global Cost

Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia

Value in Health ◽

10.1016/j.jval.2015.09.1188 ◽

2015 ◽

Vol 18 (7) ◽

pp. A460 ◽

Cited By ~ 2

Author(s):

J Vargas-Valencia ◽

J Garcia Perlaza

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

Journal of Medical Economics ◽

10.1080/13696998.2017.1285780 ◽

2017 ◽

Vol 20 (6) ◽

pp. 574-584 ◽

Cited By ~ 3

Author(s):

Fernando Rivera ◽

Manuel Valladares ◽

Salvador Gea ◽

Noemí López-Martínez

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Cost-Effectiveness Analysis of Regorafenib and Tas-102 In Refractory Metastatic Colorectal Cancer

Value in Health ◽

10.1016/j.jval.2018.04.072 ◽

2018 ◽

Vol 21 ◽

pp. S1

Author(s):

SK Cho ◽

JW Hay ◽

A Barzi

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Cost-effectiveness analysis of cytoreductive surgery and HIPEC compared to systemic chemotherapy in isolated peritoneal carcinomatosis from metastatic colorectal cancer.

10.1200/jco.2018.36.15_suppl.e18897 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e18897-e18897

Author(s):

Trevor D Hamilton ◽

Howard John Lim ◽

Andrea J MacNeill ◽

Myriam Hunink

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Peritoneal Carcinomatosis ◽

Cytoreductive Surgery ◽

Systemic Chemotherapy ◽

Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2014.09.007 ◽

2014 ◽

Vol 13 (4) ◽

pp. 219-225 ◽

Cited By ~ 23

Author(s):

Daniel A. Goldstein ◽

Qiushi Chen ◽

Turgay Ayer ◽

David H. Howard ◽

Joseph Lipscomb ◽

...

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Effectiveness Analysis ◽

Folfox Chemotherapy

KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-10-2267 ◽

2011 ◽

Vol 17 (19) ◽

pp. 6338-6346 ◽

Cited By ~ 51

Author(s):

Patricia R. Blank ◽

Holger Moch ◽

Thomas D. Szucs ◽

Matthias Schwenkglenks

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Mutation Analysis ◽

Braf Mutation ◽

RE: Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djt370 ◽

2013 ◽

Vol 106 (2) ◽

pp. djt370-djt370 ◽

Cited By ~ 1

Author(s):

L. M. Hess ◽

G. Carter ◽

L. Smolen ◽

L. Bowman ◽

P. von Hohnhorst ◽

...

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Braf Mutations ◽

Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer

10.1200/jco.2008.26.15_suppl.15090 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 15090-15090

Author(s):

M. Romeo ◽

G. Soler ◽

M. Martínez Villacampa ◽

B. Laquente ◽

A. López Doriga ◽

...

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Line Treatment ◽

Effectiveness Analysis ◽

Third Line ◽

Third Line Treatment

Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC).

10.1200/jco.2014.32.15_suppl.6527 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 6527-6527 ◽

Cited By ~ 2

Author(s):

Daniel A. Goldstein ◽

Qiushi Chen ◽

David H. Howard ◽

Joseph Lipscomb ◽

Turgay Ayer ◽

...

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Effectiveness Analysis ◽

Folfox Chemotherapy